The Omicron variant of SARS-CoV-2 is a powerful reminder that the COVID-19 pandemic, now entering its third year, will continue to have personal and public health impacts. This may be especially true for those individuals who unfortunately missed or delayed cancer screening or treatment as a result of the pandemic.
Immediate action must be taken to ensure more effective and equitable implementation of cancer screening, according to a report released by the President’s Cancer Panel.
A study led by investigators at the University of Alabama at Birmingham and Nationwide Children’s Hospital has provided additional evidence of the efficacy of virotherapy for glioblastoma.
Researchers at Yale Cancer Center showed that inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing.
FDA is investigating a possible increased risk of death with the drug Ukoniq (umbralisib) approved to treat relapsed or refractory marginal zone lymphoma.
Veru Inc. and Eli Lilly and Company entered into a clinical trial collaboration and supply agreement to evaluate the efficacy and safety of enobosarm, Veru’s first-in-class, selective androgen receptor targeting agonist, in combination with Lilly’s Verzenio (abemaciclib), a CDK4/6 inhibitor, as a second line therapy in the treatment of AR+ER+HER2- metastatic breast cancer.
The National Cancer Institute approved the following clinical research study last month.
St. Jude Children’s Research Hospital is taking on a major global health challenge—the murky quagmire of drug shortages—by partnering with the World Health Organization to prove that practical solutions are within reach.
St. Jude Children’s Research Hospital’s new $200-million Global Platform for Access to Childhood Cancer Medicines—a partnership with the World Health Organization—can be traced back to a critique from a visiting reviewer.
Many global health professionals have dreamed about solving drug shortages, and St. Jude Children’s Research Hospital is taking the first steps toward eliminating the problem, said Carlos Rodriguez-Galindo, director of St. Jude Global.
